Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 6 Sept 2026

PSA Doubling Time and Lu-177 PSMA Treatment Timing

If your PSA keeps rising despite hormone therapy, PSA doubling time is one of the clearest signals that a treatment reassessment is due. This article explains what PSADT means for men with mCRPC and when to ask about Lu-177 PSMA therapy.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 6 Sept 2026
PSA Doubling Time and Lu-177 PSMA Treatment Timing

This article is for men with metastatic castration-resistant prostate cancer (mCRPC) - a form of advanced prostate cancer that no longer responds to hormone therapy - and for their families. If your PSA level keeps climbing despite treatment, you probably want to know: what does this number mean, and when should you try a different treatment? PSA doubling time tells your doctors how fast your cancer is growing. Understanding it helps you know when to ask your doctor about lutetium Lu-177 vipivotide tetraxetan, a therapy approved for certain mCRPC patients.

Quick answer: PSA doubling time - often written as PSADT - is how many months it takes for your PSA level to double. A shorter doubling time, usually under six months, means your cancer is growing faster and you should reassess your treatment soon. In mCRPC, PSADT alone does not tell you if you qualify for Lu-177 PSMA therapy. Eligibility depends on a PSMA-PET scan. But a rapidly shortening PSADT usually signals that you should have the PSMA-PET conversation now, not later.

What PSA doubling time actually means

Prostate-specific antigen, or PSA, is a protein made by prostate cells. In men with prostate cancer, a rising PSA usually means the cancer is growing. But the raw number only tells part of the story. How fast PSA is rising matters as much as where it stands today.

PSADT measures that speed. If your PSA was 4 ng/mL three months ago and is 8 ng/mL today, your doubling time is about three months. If it took two years to go from 4 to 8, your doubling time is about 24 months. The same PSA level can mean very different things depending on how fast it got there.

Across prostate cancer research, faster doubling times point to more aggressive disease and shorter survival. A research review on PSA velocity and doubling time in prostate cancer management shows PSADT works as a useful tool from initial diagnosis through advanced disease tracking.

How doctors calculate PSADT

Calculating PSADT requires at least two PSA measurements from the same lab, using the same test, over a meaningful time period. Most doctors prefer three or more readings spread across several months for accuracy. A single jump in PSA is not enough to find a reliable doubling time.

The formula uses logarithms because cancer growth is exponential, not linear. You do not need to do the math yourself. Memorial Sloan Kettering Cancer Center offers a free online PSADT calculator where you enter your PSA values and dates and get an estimated doubling time.

Your oncologist will likely track PSADT over several months rather than relying on one calculation. The trend - whether PSADT is getting shorter or staying the same - can be as helpful as the number itself.

What different PSADT values mean in mCRPC

There is no single cut-off that works for every man with mCRPC, but research offers useful reference points.

A PSADT under three months shows rapid, aggressive disease. A PSADT of three to six months is also concerning and usually calls for prompt treatment reassessment. A PSADT of six to twelve months shows meaningful but slower progression. A PSADT above twelve months usually shows slower disease growth, though this is not a reason to skip an eligibility review.

In non-metastatic CRPC, patients with a PSADT of 10 months or less have a higher risk of developing metastatic spread. A 2024 study on treatment timing in high-risk non-metastatic CRPC found that starting treatment at a lower PSA level in this group led to longer PSA progression-free survival. While this finding comes from a non-metastatic setting, the principle applies even more in mCRPC: acting earlier in fast-progressing disease may keep more options open.

In men who received radium-223 for bone-metastatic CRPC, those with a post-treatment PSADT of six months or less had significantly shorter overall survival compared with those whose PSA rose more slowly. This finding appeared in a peer-reviewed study on PSA kinetics as a predictor of clinical course after radium-223. Radium-223 and Lu-177 PSMA are different therapies, but this research shows how PSA kinetics consistently signal disease aggressiveness across treatment types.

PSADT is one signal among several. Disease volume on imaging, organ function, and other lab results all shape treatment decisions alongside PSA kinetics.

Does your PSA level directly determine Lu-177 PSMA eligibility?

No. Neither your raw PSA number nor your doubling time directly determines whether you qualify for Lu-177 PSMA therapy. What determines eligibility is PSMA expression - how much of the PSMA protein your tumors make - and a PSMA-PET scan measures this.

PSMA, or prostate-specific membrane antigen, is a protein that many advanced prostate cancer cells overproduce. Lu-177 PSMA therapy works by attaching a radioactive molecule to a compound that finds and binds to PSMA on cancer cells, delivering targeted radiation directly to those cells. Tumors that do not make enough PSMA will not absorb the therapy effectively. This is why the PSMA-PET scan is required as the first step in any eligibility assessment.

Your doubling time matters in another way: it tells you and your oncologist how urgently you need that PSMA-PET scan and eligibility conversation. A PSADT of three months means your disease may be progressing fast enough that delaying the evaluation by a few months could change what options remain. You can read more about interpreting your scan results in our guide to what your PSMA-PET results mean for Lu-177 eligibility.

Why timing matters when PSA is rising fast

Timing matters because your fitness for treatment changes as disease progresses. A short PSADT in mCRPC means that disease volume is expanding quickly. Rapidly spreading disease can affect kidney function, liver function, and bone marrow reserve - all of which doctors check before offering Lu-177 PSMA therapy. If any of these fall below safe levels, treatment may no longer be possible.

This does not mean every man with a rising PSA should rush to a treatment center immediately. It does mean that talking with your oncologist - and, if needed, the logistics of an eligibility review - should happen sooner rather than later. Patients seeking Lu-177 PSMA access internationally face added time considerations: getting a PSMA-PET scan, sharing imaging for clinical review, arranging a medical visa, and scheduling cycles across multiple trips all need planning time that a very short PSADT may not allow. If this is your situation, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you and what alternatives exist to begin the review process without waiting for your next scheduled clinic appointment.

Where Lu-177 PSMA fits in your treatment sequence

Lu-177 PSMA therapy is currently approved for men with mCRPC who have already received an androgen receptor pathway inhibitor, such as enzalutamide or abiraterone, and at least one taxane-based chemotherapy regimen. This is the sequence established through the VISION trial, the Phase 3 study that supported regulatory approval of lutetium Lu-177 vipivotide tetraxetan in the United States and Europe.

If your PSA is rising rapidly and you have already completed those prior treatments, you should have the PSMA-PET scan and eligibility conversation now, not after another round of treatment. If you have not yet received chemotherapy, your oncologist may consider your doubling time when deciding how to sequence your remaining options. Eligibility criteria are evolving in some settings - our article on Lu-177 PSMA now available earlier for mCRPC patients covers how this is changing.

A PSADT that is getting shorter from one measurement to the next may also signal that your current therapy is not working well. Continuing a treatment that is clearly not working delays access to something that might work better.

What PSA does during Lu-177 PSMA cycles

Once you begin Lu-177 PSMA treatment, doctors continue to monitor PSA through each cycle - but the numbers can behave in ways that look alarming without context.

In the first few weeks after an infusion, some patients see a temporary rise in PSA. This is often called a PSA flare, and it does not necessarily mean the treatment is failing. The rise may reflect cancer cells releasing PSA as they respond to the targeted radiation before being cleared. A dedicated explainer is available in our article on PSA flare after the first Lu-177 PSMA injection.

Over subsequent cycles, a meaningful PSA decline - typically defined as a fall of 50% or more from the pre-treatment level - connects with better clinical outcomes. Analysis of data from the VISION trial showed that patients whose PSA declined during lutetium Lu-177 vipivotide tetraxetan treatment had better progression-free and overall survival compared with those whose PSA did not decline. This analysis of PSA levels and clinical outcomes in the VISION trial reinforces the value of tracking PSA trends across multiple cycles, not reacting to a single data point.

Many patients find that watching PSA numbers between cycles increases anxiety and disrupts sleep. If this affects you, talk with your care team about ways to manage stress and sleep during your treatment period. For a fuller guide to reading PSA patterns across your full treatment course, see our article on reading PSA trends during Lu-177 PSMA therapy.

When to talk to your doctor

Bring up your PSA doubling time with your oncologist if any of the following apply to you:

  • Your PSA has doubled in six months or less
  • Your calculated PSADT has shortened compared with a previous measurement
  • PSA is rising despite your current treatment
  • You have completed prior hormone therapy and chemotherapy and have not yet had a PSMA-PET scan assessed for Lu-177 eligibility
  • You are planning to travel internationally for treatment and need to understand whether your timeline allows it

You can submit your recent PSA readings, PSMA-PET results, and prior treatment history for an initial review through the Lutetium Therapy contact form. If Lu-177 PSMA is not the right fit for your specific situation, a second opinion on what other options may exist is also available.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

What is PSA doubling time and why does it matter in mCRPC?

PSA doubling time (PSADT) is the number of months it takes for your PSA level to double. In metastatic castration-resistant prostate cancer, a faster doubling time suggests more aggressive disease growth. Your oncologist uses PSADT alongside imaging results and organ-function tests to judge how urgently a treatment change may be needed and whether you should be evaluated for therapies such as Lu-177 PSMA. It is one signal among several, not a standalone decision-maker.

How short does PSADT need to be before I should ask about Lu-177 PSMA eligibility?

There is no single threshold that automatically triggers the conversation, but a PSADT under six months is generally considered a sign that your disease is progressing quickly and that treatment reassessment is urgent. A PSADT under three months is especially concerning. The most important next step is to ask your oncologist about a PSMA-PET scan, which is what actually determines whether you qualify for Lu-177 PSMA therapy - not the PSA number itself.

If my PSADT is very short, am I automatically eligible for Lu-177 PSMA?

No. A short PSADT signals urgency but does not guarantee eligibility. What determines eligibility is whether your tumours express enough PSMA protein, as measured by a PSMA-PET scan. A short PSADT means you should get that scan as soon as possible. Your organ function, prior treatment history, and overall disease volume also factor into whether the therapy can be offered safely.

What is a PSA flare and does it mean Lu-177 PSMA is not working?

A PSA flare is a temporary rise in PSA in the first few weeks after a Lu-177 PSMA infusion. It does not necessarily mean the treatment is failing. It may reflect cancer cells releasing PSA as they respond to the targeted radiation. Your care team will look at PSA trends across multiple cycles rather than a single reading before drawing conclusions about whether the therapy is working.

Can PSADT change over time, and does a shortening PSADT mean my current treatment is failing?

Yes, PSADT can change over time. It may shorten as disease becomes more aggressive or if a current treatment is losing its effect, and it may lengthen in response to effective therapy. A PSADT that shortens significantly from one measurement to the next while you are on active treatment is an important signal to discuss with your oncologist, as it may indicate the current approach is no longer controlling the disease adequately.

If my PSA rises during Lu-177 PSMA treatment, should I stop the cycles?

Not necessarily. A single PSA rise during Lu-177 PSMA treatment does not automatically mean the therapy is failing, especially in the first one or two cycles where a temporary PSA flare is recognised. Treatment response is assessed over multiple cycles using PSA trends alongside imaging. Your oncologist will guide decisions about continuing or adjusting therapy based on the full clinical picture, not a single data point.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

PSA Doubling Time and Lu-177 PSMA Therapy | lutetium-therapy